Newsletter | August 8, 2019

08.08.19 -- Roundtable Discussion Reveals Biggest Biosimilar Knowledge Gaps

 
Featured Editorial
Employer Roundtable Highlights Biosimilar Knowledge Gap
 
By Anna Rose Welch, editor, Biosimilar Development

Though this event encompassed a small cross-section of employers, the discussions and questions asked about biosimilars revealed the topics that need to be considered, reiterated, and regularly reinforced.

IPR For Biosimilars: Examining The Benefits And Drawbacks
 
By John L. Abramic, partner, Steptoe & Johnson LLP

Whether Inter Partes Review (IPR) is the right choice for biosimilar developers will depend on the particular circumstances surrounding each drug candidate. But given the benefits of IPR proceedings, they must at least be considered as a potential tool for challenging patents.

Industry Insights
Viral Clearance: 7 Chromatography Column Considerations
Article | By Linnea Troeng, GE Healthcare Life Sciences

Viral clearance studies are a critical part of the production of biologics. However, performing studies that are accurate and cost-effective can be challenging. Here are seven things to consider while performing your next chromatography viral clearance study.

Nonaffinity Chromatography Resin Alternative For Capture Purification Of Antibodies
Application Note | By Payal Khandelwal and Mark Snyder, Bio-Rad Laboratories, Inc.

Protein A affinity purification has multiple limitations in terms of productivity at manufacturing scale and the costs associated with making commercial antibodies, especially biosimilars. 

Sponsor
  Festival Of Biologics 2019
 

October 15 to 17, 2019 | Basel, Switzerland

The Festival of Biologics 2019 will address the strategic and commercial aspects of discovering, developing, and bringing new biologics to patients with high-level, global speakers from Big Pharma, biotech, academia, and industry. We will bring you three days packed full of top-level science, data and case studies, workshops, roundtables, and networking opportunities. With 350 speakers and 1,500 attendees, this is an event not to be missed.

Connect With Biosimilar Development:
      Twitter